Schrodinger Signs Research Partnership With Novartis for New Drug Discovery, Development

MT Newswires Live11-12 22:41

Schrodinger (SDGR) said Tuesday it has signed a research partnership and license deal with Novartis (NVS), with Novartis paying $150 million upfront and Schrodinger having the potential to earn up to $2.3 billion in milestone payments plus royalties.

The company said it will work with Novartis to identify and advance multiple drug candidates for development within Novartis's therapeutic portfolio. Under terms of the deal, Schrodinger will contribute to candidate discovery, while Novartis will manage clinical trials, manufacturing, and commercialization.

Schrodinger said it also signed an expanded software license agreement which will allow Novartis broad access to Schrodinger's computational drug discovery platform.

Shares of Schrodinger were up nearly 14% in recent Tuesday trading, while Novartis was down 0.5%

Price: 23.21, Change: +3.67, Percent Change: +18.76

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment